MX2007004425A - Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. - Google Patents

Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.

Info

Publication number
MX2007004425A
MX2007004425A MX2007004425A MX2007004425A MX2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A
Authority
MX
Mexico
Prior art keywords
solvent
atorvastatin hemi
amorphous atorvastatin
dissolving
calcium
Prior art date
Application number
MX2007004425A
Other languages
English (en)
Inventor
Michael Pinchasov
Dalia Maidan-Hanoch
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2007004425A publication Critical patent/MX2007004425A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan procesos novedosos para la preparacion de sal de hemi-calcio de atorvastatina amorfa, que comprenden disolver la sal de hemi-calcio de atorvastatina en ciertos solventes organicos y remover el solvente por ejemplo mediante secado por aspersion, evaporacion al vacio rapida, y/o evaporacion de pelicula delgada. Las realizaciones preferidas de estos procesos para preparar la sal de hemi-calcio de atorvastatina amorfa son reproducibles, aplicables a gran escala y no incluyen el uso de hidrocarburos.
MX2007004425A 2004-10-18 2005-10-18 Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. MX2007004425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62002204P 2004-10-18 2004-10-18
PCT/US2005/037751 WO2006045018A1 (en) 2004-10-18 2005-10-18 Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent

Publications (1)

Publication Number Publication Date
MX2007004425A true MX2007004425A (es) 2007-06-07

Family

ID=35709256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004425A MX2007004425A (es) 2004-10-18 2005-10-18 Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.

Country Status (12)

Country Link
US (1) US20060106230A1 (es)
EP (1) EP1716114A1 (es)
JP (1) JP2007515430A (es)
KR (2) KR20090033405A (es)
CN (1) CN101039906A (es)
CA (1) CA2582087A1 (es)
DE (1) DE05810535T1 (es)
ES (1) ES2272206T1 (es)
IL (1) IL182068A0 (es)
MX (1) MX2007004425A (es)
TW (2) TW200942516A (es)
WO (1) WO2006045018A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101538237B (zh) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
KR101050722B1 (ko) * 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
IN191236B (es) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
PT1235799E (pt) 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ATE452871T1 (de) * 2002-03-18 2010-01-15 Biocon Ltd Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse
WO2003099785A1 (en) 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
RU2330840C1 (ru) * 2004-04-16 2008-08-10 Пфайзер Продактс Инк. Способ получения аморфного кальций аторвастатина
JP2008510798A (ja) * 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension

Also Published As

Publication number Publication date
ES2272206T1 (es) 2007-05-01
KR20090033405A (ko) 2009-04-02
TW200942516A (en) 2009-10-16
WO2006045018A1 (en) 2006-04-27
TW200630335A (en) 2006-09-01
CA2582087A1 (en) 2006-04-27
KR20070054730A (ko) 2007-05-29
IL182068A0 (en) 2007-07-24
CN101039906A (zh) 2007-09-19
EP1716114A1 (en) 2006-11-02
DE05810535T1 (de) 2007-04-19
JP2007515430A (ja) 2007-06-14
US20060106230A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MX2007004425A (es) Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
RU2247113C2 (ru) Способ получения аморфного аторвастатина
WO2008067215A3 (en) Vials and apparatus for obtaining an aliquot of a sample
UA87492C2 (en) Regiospecific synthesis of rapamycin 42-ester derivatives
DE60041704D1 (de) Ungen
MX2009010688A (es) Metodo para remover color del material polimerico.
WO2009084023A3 (en) Amorphous ramelteon and process for the preparation thereof
ES2524585T3 (es) Sistema catalizador para la polimerización de olefinas, su producción y su uso
EP1550853A4 (en) BIOCHEMICAL CONTAINER
DE602005020717D1 (de) Verfahren zur Beschichtung von nanostrukturierte Elektroden
WO2009011844A8 (en) Processes for solifenacin preparation
ATE495166T1 (de) Verbessertes verfahren zur zubereitung von rabeprazol-natrium
CN103245717A (zh) 高压成型基质薄膜辅助-激光解析离解质谱定量分析方法
Ren et al. Synthesis of a small-molecule library with skeletal diversity from Hemslecin A via the reaction-discovery strategy
CA2479005A1 (en) Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size
WO2007017244A3 (en) A PROCESS FOR THE PURIFICATION OF SUBSTITUTED 2-(2-PYRIDYLMETHYL)SULFINYL-lH-BENZIMIDAZOLE COMPOUNDS BY PRECIPITATION IN THE PRESENCE OF A QUATERNARY AMMONIUM SALT
AU2003233064A1 (en) Process for the preparation of the amorphous form of atorvastatin calcium salt
AR048756A1 (es) Procedimiento para formar atorvastatina amorfa
WO2008156080A1 (ja) 質量分析用プレートとそれを用いた薄層クロマトグラフィ－質量分析方法及び装置
DE60232006D1 (de) Rückgewinnung und recycling chiraler weinsäureverbindungen zur racematspaltung
IL155545A (en) Solvate form of cabergoline
RS54174B1 (en) PROCEDURE FOR OBTAINING AMORPHIC LERCANIDIPINE
AU2003233053A1 (en) Aqueous liquid compositions of reactive cyclodextrin derivatives and a finishing process using the said composition
Thi et al. Synthesis of new bioisosteric hemiasterlin analogues with extremely high cytotoxicity
TW200507110A (en) Coating composition and low dielectric constant porous silica material produced therewith